Company / Revenue
Editas Medicine, Inc. Revenue History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$32.3M
FY2025
5-year range
$19.7M / $90.7M
FY2021-FY2025
Trend
+63.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue returned to growth in FY2025 after 2 years of decline, reaching $32M.
Based on SEC 10-K filings.
$32M in FY2025 with a 5-year CAGR of +0.2%.
Improved from $26M to $32M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -29.1%
- 5-Year CAGR
- +0.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +0.2%, indicating consistent growth.
- In FY2025, revenue increased 63.9% year-over-year.
- Peak revenue was recorded in FY2022.
- Lowest revenue in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $32.3M | +63.9% |
| FY2024 | $19.7M | -22.8% |
| FY2023 | $25.5M | -71.8% |
| FY2022 | $90.7M | +341.9% |
| FY2021 | $20.5M | -35.7% |
| FY2020 | $31.9M | +132.6% |
| FY2019 | $13.7M | +126.8% |
| FY2018 | $6.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026